Tofacitinib as a possible treatment for skin thickening in diffuse cutaneous systemic sclerosis

Objectives. To analyse the effectiveness of tofacitinib for the treatment of refractory skin thickening in dcSSc. Methods. Data from 10 patients with dcSSc treated with tofacitinib (5 mg twice daily) were analysed. A total of 12 dcSSc patients treated with intensive conventional immunosuppressants were selected as the historical comparator group. A clinically relevant response was defined as a decrease in the modified Rodnan skin score (mRSS) of >5 points and >= 25% from baseline. Clinical indicators were compared between the two groups to evaluate the effect of tofacitinib. Results. The mRSS significantly improved the first month after tofacitinib treatment, with a mean change in the mRSS of -3.7 (95% CI -5.52, -1.88; P =0.001) and greater than the comparators at 6 months [-10.0 (95% CI -14.74, -5.26) vs -4.1 (95% CI -7.49, -0.73), P =0.026]. Tofacitinib-treated patients had a significantly shorter response time than the comparators (P =0.015 by log-rank test), with overall response rates of 20% (2/10) vs 0% (0/12) and 60% (6/10) vs 16.7% (2/12) at 1 and 3 months, respectively. Conclusion. Our results indicate that tofacitinib may be as effective as or even better than intensive conventional immunosuppressants, with a quicker and higher response rate in refractory dcSSc patients with progressive skin thickness.

Automated summary

The study analyzed the effectiveness of tofacitinib in treating refractory skin thickening in dcSSc patients, showing improvements in skin score in a short period and a better performance compared to the control group. Tofacitinib-treated patients had a significantly shorter response time and higher response rates than the comparators.